A highli selective HDAC6 inhibitor MPT0G211: application in cancer and neurodegenerative diseases

According to Centers for Disease Control and Prevention (CDC), cancer and Alzheimer’s disease are number two and seven on the list of top 10 leading causes of death in 2018. For both diseases, there is an urgent need to improve the current treatment for better clinical outcomes. Cancer is responsible for an estimated 8 million deaths in 2018; this number will reach 24 million in estimation in 2035. Alzheimer's disease (AD) has received much attention recently owing to the population ageing. The aging population will reach 100 million in 2025, and 6% of them will possibly be diagnosed with AD. Despite the highly unmet medical needs, only few drugs have been approved for AD, which can only provide symptom relief.

ATP BioPharm is an energized start-up biotech company spun out from Taipei Medical University with a focus on drug development for unmet medical needs. Our company is positioned to deliver a best-in-class small molecule from preclinical to clinical stage. ATP BioPharm now possesses a patent-protected HDAC6 inhibitor, MPT0G211.

A Selective HDAC6 Inhibitor, MPT0G211

• High selectivity, high sensitivity

        (Superior to HDAC6 inhibitor, ACY-1215 and Acy-241, both developed by Celgene)

• Considerable safety profile
• Multiple myeloma combination therapy, Alzheimer’s disease, and neuropathic pain
• IND enabling studies are nearly completed; will enter Phase I clinical trials in 2021
• Comprehensive patent portfolio
• Coaching provided by Silicon Valley Advantage accelerator
• Exclusive licensed to ATP BioPharm from Taipei Medical University

 Look for: 

technology transfer, out-licensing or co-development opportunities.

 InnoZone